Overview
The marketing authorisation for Alpivab has been withdrawn at the request of the marketing-authorisation holder.
Alpivab : EPAR - Medicine overview
English (EN) (650.2 KB - PDF)
български (BG) (1.27 MB - PDF)
español (ES) (1.2 MB - PDF)
čeština (CS) (1.26 MB - PDF)
dansk (DA) (1.2 MB - PDF)
Deutsch (DE) (1.2 MB - PDF)
eesti keel (ET) (1.2 MB - PDF)
ελληνικά (EL) (1.28 MB - PDF)
français (FR) (1.2 MB - PDF)
hrvatski (HR) (1.22 MB - PDF)
italiano (IT) (1.2 MB - PDF)
latviešu valoda (LV) (1.26 MB - PDF)
lietuvių kalba (LT) (1.22 MB - PDF)
magyar (HU) (1.25 MB - PDF)
Malti (MT) (1.26 MB - PDF)
Nederlands (NL) (1.2 MB - PDF)
polski (PL) (1.25 MB - PDF)
português (PT) (1.2 MB - PDF)
română (RO) (1.22 MB - PDF)
slovenčina (SK) (1.26 MB - PDF)
slovenščina (SL) (1.25 MB - PDF)
Suomi (FI) (1.2 MB - PDF)
svenska (SV) (1.2 MB - PDF)
Product information
Alpivab : EPAR - Product Information
English (EN) (1.57 MB - PDF)
български (BG) (3.2 MB - PDF)
español (ES) (2.3 MB - PDF)
čeština (CS) (2.77 MB - PDF)
dansk (DA) (2.25 MB - PDF)
Deutsch (DE) (2.3 MB - PDF)
eesti keel (ET) (2.23 MB - PDF)
ελληνικά (EL) (3.21 MB - PDF)
français (FR) (2.29 MB - PDF)
hrvatski (HR) (2.31 MB - PDF)
íslenska (IS) (2.25 MB - PDF)
italiano (IT) (2.28 MB - PDF)
latviešu valoda (LV) (2.89 MB - PDF)
lietuvių kalba (LT) (2.37 MB - PDF)
magyar (HU) (2.75 MB - PDF)
Malti (MT) (2.78 MB - PDF)
Nederlands (NL) (2.27 MB - PDF)
norsk (NO) (2.24 MB - PDF)
polski (PL) (2.84 MB - PDF)
português (PT) (2.28 MB - PDF)
română (RO) (2.4 MB - PDF)
slovenčina (SK) (2.76 MB - PDF)
slovenščina (SL) (2.71 MB - PDF)
Suomi (FI) (2.25 MB - PDF)
svenska (SV) (2.26 MB - PDF)
Latest procedure affecting product information: T/0004
20/11/2020
This medicine’s product information is available in all official EU languages.
Select 'available languages' to access the language you need.
Product information documents contain:
- summary of product characteristics (annex I);
- manufacturing authorisation holder responsible for batch release (annex IIA);
- conditions of the marketing authorisation (annex IIB);
- labelling (annex IIIA);
- package leaflet (annex IIIB).
Alpivab : EPAR - All Authorised presentations
English (EN) (581.31 KB - PDF)
български (BG) (1.17 MB - PDF)
español (ES) (1.13 MB - PDF)
čeština (CS) (1.15 MB - PDF)
dansk (DA) (1.12 MB - PDF)
Deutsch (DE) (1.12 MB - PDF)
eesti keel (ET) (1.12 MB - PDF)
ελληνικά (EL) (1.17 MB - PDF)
français (FR) (1.12 MB - PDF)
hrvatski (HR) (1.14 MB - PDF)
íslenska (IS) (1.13 MB - PDF)
italiano (IT) (1.12 MB - PDF)
latviešu valoda (LV) (1.16 MB - PDF)
lietuvių kalba (LT) (1.14 MB - PDF)
magyar (HU) (1.15 MB - PDF)
Malti (MT) (1.16 MB - PDF)
Nederlands (NL) (1.13 MB - PDF)
norsk (NO) (1.12 MB - PDF)
polski (PL) (1.16 MB - PDF)
português (PT) (1.13 MB - PDF)
română (RO) (1.14 MB - PDF)
slovenčina (SK) (1.16 MB - PDF)
slovenščina (SL) (1.15 MB - PDF)
Suomi (FI) (1.12 MB - PDF)
svenska (SV) (1.13 MB - PDF)
Product details
- Name of medicine
- Alpivab
- Active substance
- Peramivir
- International non-proprietary name (INN) or common name
- peramivir
- Therapeutic area (MeSH)
- Influenza, Human
- Anatomical therapeutic chemical (ATC) code
- J05AH03
Pharmacotherapeutic group
Antivirals for systemic useTherapeutic indication
Alpivab is indicated for the treatment of uncomplicated influenza in adults and children from the age of 2 years.
Authorisation details
- EMA product number
- EMEA/H/C/004299
- Marketing authorisation holder
- Biocryst
Biocryst
Atlantic Avenue
Westpark Business Campus
Shannon V14 YX01
Ireland - Marketing authorisation issued
- 13/04/2018
- Revision
- 2
Assessment history
Alpivab : EPAR - Procedural steps taken and scientific information after authorisation
English (EN) (1.2 MB - PDF)
News on Alpivab
More information on Alpivab
Public statement on Alpivab: Withdrawal of the marketing authorisation in the European Union
English (EN) (129.27 KB - PDF)